Is missing (Short communication)

Psoriasis is a chronic inflammatory skin disease whose pathogenesis involves not only cutaneous inflammation but also intestinal dysbiosis and oxidative stress (OxS). Monoclonal antibodies targeting interleukin (IL)-17 and IL-23 have demonstrated significant immunomodulatory effects; however, their impact on systemic parameters requires further investigation. We conducted a study on 33 patients with plaque psoriasis treated with anti-IL-17 or anti-IL-23 monoclonal antibodies. Dermatological parameters (Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI)), biomarkers of intestinal dysbiosis (trimethylamine-N-oxide (TMAO)) and OxS (reactive oxygen metabolites (d-ROMs) and oxidized LDL (oxLDL)) were evaluated. Anthropometric, metabolic, and adipose-derived hormonal parameters (adipokines) were also monitored. After 16 weeks of therapy, significant improvements were observed in PASI and DLQI scores (p < 0.001). TMAO levels were significantly reduced (p = 0.02), as were d-ROMs and oxLDL (p < 0.001). No significant changes were found in weight, body mass index, lipid profile, or adipokine levels (visfatin, leptin and adiponectin). Our data indicate that monoclonal antibody therapy not only improves psoriasis severity but also exerts beneficial effects on systemic biomarkers of dysbiosis and OxS, independent of metabolic or hormonal changes. These findings suggest a systemic mechanism of action, supporting a multifactorial therapeutic effect with potential implications for the prevention of cardiovascular risk.

Dermoscopy is widely used for the diagnosis of skin cancers and it increases the accuracy of basal cell carcinoma (BCC) detection. The dermoscopic criteria of BCC have recently been updated and they can be divided into three categories: vascular, pigment-related, and nonvascular/nonpigmentrelated. The objective of our multicentre retrospective study was to report the validity of a new dermoscopic pigment-related feature utilized to detect pigmented BCC (pBCC) (i.e., brown homogeneous blotches (BHB)). Cases of pBCC were collected from the databases of IDI-IRCCS of Rome and from three Italian private dermatology centres. BHB were defined as the presence of circumscribed areas of brown homogeneous pigmentation which are devoid of any dermoscopic specific arrangement (net, fat fingers, etc.) and of other internal dermoscopic structures, except for occasional vascular ones, such as arborizing vessels or globules/dots. Controls included melanocytic and non-melanocytic lesions. We examined images of 270 pigmented lesions (female 145; 51.8%) including 90 histopathological proven pBCC and 180 control cases (i.e., 90 melanocytic and 90 non-melanocytic lesions). BHB were present in 61 cases of 90 pBCC. These results showed a sensibility of 67.8 and a specificity of 93.3 with a positive predictive value of 83.6, negative predictive value of 85.3, posLR 10.2, negLR 0.3; OR 29.4, P value<0.001. Our multicentre retrospective study showed that the BHB may represent a new dermoscopic criterion for the diagnosis of pBCC.

Hidradenitis suppurativa (HS) is a chronic, skin-immunemediated inflammatory disease (sIMID), with a high impact on quality of life (QoL). Data on clinical management, comorbidities, psychosocial burden, and psychiatric disorders in pediatric patients with HS are scarce. The aim of our study was to compare clinical characteristics and patient-reported outcome measures (PROMs) for health-related quality of life (HRQoL) in adult and pediatric patients with HS. Data were collected on 601 patients with HS, 60 of whom (10.0%) were pediatric. The psychological and HRQoL impact was generally higher in adults than children, but it was also noteworthy in pediatric patients. Early diagnosis and interventions based on education for the patients and their families and psychological support are the key to optimal disease management and adherence. Our study underlines the need for screening for HS-associated psychiatric disorders and for using age-specific tools to evaluate HRQoL. A multidisciplinary approach involving several specialists is needed, as well as liaison with primary care specialists to improve care and management of comorbidities and psychological issues in patients with HS.